InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,196.21
(
0.30%
)
US TECH 100
17,657.61
(
0.27%
)
Dow Jones
38,927.32
(
0.19%
)
Brent Oil
82.98
(
-0.60%
)
Bitcoin
63,781.55
(
0.97%
)
Post# of 470
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

apollo1452

Send PM Follow Ignore
Followers 13
Posts 559
Boards Moderated 0
Alias Born 12/31/2012

apollo1452

Re: murocman post# 91

Thursday, 09/15/2016 11:48:17 AM

Thursday, September 15, 2016 11:48:17 AM

Post# of 470
Agree $7-$8 short term, $10+ by Q1 2017 IMO. Just need the losing shorts to go thru their covering manipulation madness & ARLZ will head into clear skies. Shorties finding out that it's a Bad Idea to bet against CEO Adrian Adams.
Yosprala USA /Zontivity sales starting in Oct 2016
Filing for approval of Yosprala in the EU & Canada on deck, filing in Q4 2016 for approval of Treximet/MT 400 in Canada
Just like his previous companies, CEO Adams is positioning ARLZ to be sold at a healthy premium. Patience, let it play out IMO.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up